Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Tuesday reported positive three-year antibody persistence data for its single-dose chikungunya vaccine, IXCHIQ.
The data demonstrated sustained high levels of neutralising antibodies in both younger and older adults.
These findings confirm the long-lasting protective immunity induced by IXCHIQ, reinforcing its potential to significantly reduce the burden of chikungunya disease.
The IXCHIQ vaccine is currently approved in the United States, Europe and Canada for adults aged 18 and older. Valneva is pursuing label extensions to include adolescents and is working to expand access to the vaccine in low and middle-income countries.
USANA Health Sciences acquires controlling stake in Hiya Health for USD205m
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine